Stockreport

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis.TibuSURE launches with the initiation of its first clinic [Read more]